Graig Suvannavejh
Stock Analyst at Mizuho
(2.02)
# 1,552
Out of 4,412 analysts
118
Total ratings
38.37%
Success rate
-9.02%
Average return
Main Sectors:
Top Industries:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Buy | $82 → $96 | $73.26 | +31.04% | 8 | Apr 22, 2024 | |
| IMRX Immuneering | Maintains: Buy | $20 → $8 | $1.47 | +444.22% | 1 | Apr 2, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $108 → $109 | $71.71 | +52.00% | 14 | Mar 28, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Neutral | $3.5 | $1.45 | +141.38% | 1 | Mar 27, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $60 | $49.86 | +20.34% | 3 | Mar 27, 2024 | |
| AMLX Amylyx Pharmaceuticals | Reiterates: Buy | $27 → $32 | $1.76 | +1,718.18% | 4 | Mar 8, 2024 | |
| IMCR Immunocore Holdings | Maintains: Buy | $86 → $90 | $58.46 | +53.95% | 5 | Mar 5, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $42 → $40 | $29.32 | +36.43% | 14 | Feb 27, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | $30 → $39 | $16.75 | +132.84% | 3 | Feb 16, 2024 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $25 → $45 | $42.47 | +5.96% | 9 | Feb 16, 2024 | |
| ADVM Adverum Biotechnologies | Maintains: Buy | $20 → $40 | $9.19 | +335.26% | 3 | Feb 6, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $45 → $40 | $38.57 | +3.71% | 4 | Jan 18, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $17 → $10 | $4.91 | +103.67% | 5 | Nov 27, 2023 | |
| ALEC Alector | Maintains: Buy | $10 → $9 | $5.25 | +71.43% | 4 | Nov 17, 2023 | |
| BTAI BioXcel Therapeutics | Reiterates: Neutral | $4 | $2.63 | +52.09% | 8 | Aug 23, 2023 | |
| ATHA Athira Pharma | Maintains: Buy | $6 → $5 | $1.92 | +160.42% | 2 | May 15, 2023 | |
| IMTX Immatics | Initiates: Buy | $12 | $10.01 | +19.88% | 2 | Mar 31, 2023 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $15 | $2.71 | +453.51% | 1 | Mar 31, 2023 | |
| INSM Insmed | Initiates: Buy | $28 | $24.80 | +12.90% | 1 | Dec 9, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $31 → $35 | $38.28 | -8.57% | 5 | Nov 10, 2022 | |
| KOD Kodiak Sciences | Maintains: Neutral | $9 → $8 | $3.28 | +143.90% | 6 | Nov 10, 2022 | |
| CYTK Cytokinetics | Maintains: Buy | $71 → $57 | $65.34 | -12.76% | 2 | May 24, 2022 | |
| TGTX TG Therapeutics | Maintains: Sell | $8 → $5 | $13.47 | -62.88% | 3 | Apr 19, 2022 | |
| VALN Valneva SE | Initiates: Buy | n/a | $7.64 | - | 1 | Jun 1, 2021 | |
| DSGN Design Therapeutics | Initiates: Neutral | n/a | $3.78 | - | 1 | Apr 20, 2021 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | n/a | $16.17 | - | 1 | Apr 19, 2021 | |
| VOR Vor Biopharma | Initiates: Sell | n/a | $1.69 | - | 1 | Mar 2, 2021 | |
| IPHA Innate Pharma | Initiates: Neutral | n/a | $2.27 | - | 1 | Nov 24, 2020 | |
| ARQT Arcutis Biotherapeutics | Upgrades: Buy | n/a | $8.47 | - | 2 | Nov 9, 2020 | |
| GLPG Galapagos NV | Downgrades: Sell | n/a | $28.78 | - | 1 | Oct 21, 2020 | |
| PRLD Prelude Therapeutics | Initiates: Neutral | n/a | $4.07 | - | 1 | Oct 20, 2020 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Sell | n/a | $109.46 | - | 1 | Sep 14, 2020 |
Intra-Cellular Therapies
Apr 22, 2024
Maintains: Buy
Price Target: $82 → $96
Current: $73.26
Upside: +31.04%
Immuneering
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.47
Upside: +444.22%
Axsome Therapeutics
Mar 28, 2024
Maintains: Buy
Price Target: $108 → $109
Current: $71.71
Upside: +52.00%
Corvus Pharmaceuticals
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $1.45
Upside: +141.38%
Apellis Pharmaceuticals
Mar 27, 2024
Maintains: Neutral
Price Target: $60
Current: $49.86
Upside: +20.34%
Amylyx Pharmaceuticals
Mar 8, 2024
Reiterates: Buy
Price Target: $27 → $32
Current: $1.76
Upside: +1,718.18%
Immunocore Holdings
Mar 5, 2024
Maintains: Buy
Price Target: $86 → $90
Current: $58.46
Upside: +53.95%
Harmony Biosciences Holdings
Feb 27, 2024
Maintains: Buy
Price Target: $42 → $40
Current: $29.32
Upside: +36.43%
EyePoint Pharmaceuticals
Feb 16, 2024
Maintains: Buy
Price Target: $30 → $39
Current: $16.75
Upside: +132.84%
Cerevel Therapeutics Holdings
Feb 16, 2024
Maintains: Neutral
Price Target: $25 → $45
Current: $42.47
Upside: +5.96%
Adverum Biotechnologies
Feb 6, 2024
Maintains: Buy
Price Target: $20 → $40
Current: $9.19
Upside: +335.26%
Halozyme Therapeutics
Jan 18, 2024
Maintains: Neutral
Price Target: $45 → $40
Current: $38.57
Upside: +3.71%
Terns Pharmaceuticals
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $4.91
Upside: +103.67%
Alector
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $5.25
Upside: +71.43%
BioXcel Therapeutics
Aug 23, 2023
Reiterates: Neutral
Price Target: $4
Current: $2.63
Upside: +52.09%
Athira Pharma
May 15, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $1.92
Upside: +160.42%
Immatics
Mar 31, 2023
Initiates: Buy
Price Target: $12
Current: $10.01
Upside: +19.88%
Vigil Neuroscience
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $2.71
Upside: +453.51%
Insmed
Dec 9, 2022
Initiates: Buy
Price Target: $28
Current: $24.80
Upside: +12.90%
Rhythm Pharmaceuticals
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $38.28
Upside: -8.57%
Kodiak Sciences
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.28
Upside: +143.90%
Cytokinetics
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $65.34
Upside: -12.76%
TG Therapeutics
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $13.47
Upside: -62.88%
Valneva SE
Jun 1, 2021
Initiates: Buy
Price Target: n/a
Current: $7.64
Upside: -
Design Therapeutics
Apr 20, 2021
Initiates: Neutral
Price Target: n/a
Current: $3.78
Upside: -
Edgewise Therapeutics
Apr 19, 2021
Initiates: Neutral
Price Target: n/a
Current: $16.17
Upside: -
Vor Biopharma
Mar 2, 2021
Initiates: Sell
Price Target: n/a
Current: $1.69
Upside: -
Innate Pharma
Nov 24, 2020
Initiates: Neutral
Price Target: n/a
Current: $2.27
Upside: -
Arcutis Biotherapeutics
Nov 9, 2020
Upgrades: Buy
Price Target: n/a
Current: $8.47
Upside: -
Galapagos NV
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $28.78
Upside: -
Prelude Therapeutics
Oct 20, 2020
Initiates: Neutral
Price Target: n/a
Current: $4.07
Upside: -
Jazz Pharmaceuticals
Sep 14, 2020
Downgrades: Sell
Price Target: n/a
Current: $109.46
Upside: -